Compare Medpace Holdings Inc (MEDP) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Charles Schwab Corporation Common Stock — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Charles Schwab Corporation Common Stock trades at $96.7 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 10× Medpace Holdings Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| MEDP | SCHW | |
|---|---|---|
Market Cap | $16.82B | $167.52B |
Volume | 223,093 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $630.19 | $113.65 |
52-Week Low | $393.42 | $85.35 |
Typical Hold Time | 14 Days | 85 Days |
Enterprise Value | $16.44B | $153.97B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
Charles Schwab (SCHW) trades at $96.87, up 1.35% with strong fundamentals including 37% net margin and consistent earnings beats. Technical indicators show bearish momentum near key support at $96, while fundamentals reveal robust revenue growth to $23.92B in 2025 and improving cash flow. The company demonstrates operational strength with client assets reaching $13.41T in August 2026 and strategic AI integration with Anthropic.
Outlook remains positive with 56.9% analyst buy ratings and $120.33 consensus target, though near-term technical weakness and competitive pressures pose risks. Earnings momentum and market share gains in the growing e-brokerage sector support upside potential, while interest rate sensitivity and execution risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
